Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | TFPI | P10646 | 3/20 | 0.57 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 4/20 | 0.56 |
| ▸ | NPY4R | P50391 | 4/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.56 |
| ▸ | NPY1R | P25929 | 3/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988048 | 0.90 | NPY2R (0.64) | CALCRTFPINPY2RNPY4RNPY5R | |
| SCHEMBL30176437 | 0.90 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30176414 | 0.90 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30073900 | 0.89 | CALCR (0.66) | CALCROPRM1OPRD1OPRK1TFPI | |
| SCHEMBL29949429 | 0.88 | TFPI (0.62) | CALCROPRM1OPRD1OPRK1TFPI | |
| SCHEMBL29949393 | 0.88 | CALCRL (0.59) | CALCROPRM1OPRD1OPRK1CALCRL | |
| SCHEMBL31182463 | 0.88 | CALCR (0.60) | CALCRCALCRLNPY2RNPY4RNPY5R | |
| SCHEMBL30824299 | 0.88 | CALCR (0.61) | CALCROPRM1OPRD1OPRK1TFPI | |
| SCHEMBL29655865 | 0.88 | OPRD1 (0.61) | CALCROPRM1OPRD1OPRK1 | |
| SCHEMBL30906484 | 0.88 | TFPI (0.59) | CALCROPRM1OPRD1OPRK1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294433-A1 | IMMUNOGENIC COMPOSITION, USE AND METHODS | GlaxoSmithKline Biologicals SA (BE) | 2023-12-27 | — | — | EP | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| WO-2022175423-A1 | IMMUNOGENIC COMPOSITION, USE AND METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-08-25 | — | — | WO | disclosed |
| EP-4009951-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GlaxoSmithKline Biologicals S.A. (BE) | 2022-06-15 | — | — | EP | disclosed |
| EP-4010014-A1 | IMMUNOGENIC COMPOSITION | GlaxoSmithKline Biologicals S.A. (BE) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | CALCR 415/4885OPRM1 3724/4885OPRD1 969/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | CALCR 415/4885OPRM1 3724/4885OPRD1 969/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | CALCR 1308/4885OPRM1 2604/4885OPRD1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.